Cargando…

The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation

A sequence variation (I148M) in patatin‐like phospholipase domain‐containing protein 3 (PNPLA3) is strongly associated with fatty liver disease, but the underlying mechanism remains obscure. In this study, we used knock‐in (KI) mice (Pnpla3(148M/M)) to examine the mechanism responsible for accumulat...

Descripción completa

Detalles Bibliográficos
Autores principales: BasuRay, Soumik, Smagris, Eriks, Cohen, Jonathan C., Hobbs, Helen H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605398/
https://www.ncbi.nlm.nih.gov/pubmed/28520213
http://dx.doi.org/10.1002/hep.29273
_version_ 1783264982514794496
author BasuRay, Soumik
Smagris, Eriks
Cohen, Jonathan C.
Hobbs, Helen H.
author_facet BasuRay, Soumik
Smagris, Eriks
Cohen, Jonathan C.
Hobbs, Helen H.
author_sort BasuRay, Soumik
collection PubMed
description A sequence variation (I148M) in patatin‐like phospholipase domain‐containing protein 3 (PNPLA3) is strongly associated with fatty liver disease, but the underlying mechanism remains obscure. In this study, we used knock‐in (KI) mice (Pnpla3(148M/M)) to examine the mechanism responsible for accumulation of triglyceride (TG) and PNPLA3 in hepatic lipid droplets (LDs). No differences were found between Pnpla3(148M/M) and Pnpla3(+/+) mice in hepatic TG synthesis, utilization, or secretion. These results are consistent with TG accumulation in the Pnpla3(148M/M) mice being caused by impaired TG mobilization from LDs. Sucrose feeding, which is required to elicit fatty liver in KI mice, led to a much larger and more persistent increase in PNPLA3 protein in the KI mice than in wild‐type (WT) mice. Inhibition of the proteasome (bortezomib), but not macroautophagy (3‐methyladenine), markedly increased PNPLA3 levels in WT mice, coincident with the appearance of ubiquitylated forms of the protein. Bortezomib did not increase PNPLA3 levels in Pnpla3(148M/M) mice, and only trace amounts of ubiquitylated PNPLA3 were seen in these animals. Conclusion: These results are consistent with the notion that the 148M variant disrupts ubiquitylation and proteasomal degradation of PNPLA3, resulting in accumulation of PNPLA3‐148M and impaired mobilization of TG from LDs. (Hepatology 2017;66:1111‐1124).
format Online
Article
Text
id pubmed-5605398
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-56053982017-10-25 The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation BasuRay, Soumik Smagris, Eriks Cohen, Jonathan C. Hobbs, Helen H. Hepatology Original Articles A sequence variation (I148M) in patatin‐like phospholipase domain‐containing protein 3 (PNPLA3) is strongly associated with fatty liver disease, but the underlying mechanism remains obscure. In this study, we used knock‐in (KI) mice (Pnpla3(148M/M)) to examine the mechanism responsible for accumulation of triglyceride (TG) and PNPLA3 in hepatic lipid droplets (LDs). No differences were found between Pnpla3(148M/M) and Pnpla3(+/+) mice in hepatic TG synthesis, utilization, or secretion. These results are consistent with TG accumulation in the Pnpla3(148M/M) mice being caused by impaired TG mobilization from LDs. Sucrose feeding, which is required to elicit fatty liver in KI mice, led to a much larger and more persistent increase in PNPLA3 protein in the KI mice than in wild‐type (WT) mice. Inhibition of the proteasome (bortezomib), but not macroautophagy (3‐methyladenine), markedly increased PNPLA3 levels in WT mice, coincident with the appearance of ubiquitylated forms of the protein. Bortezomib did not increase PNPLA3 levels in Pnpla3(148M/M) mice, and only trace amounts of ubiquitylated PNPLA3 were seen in these animals. Conclusion: These results are consistent with the notion that the 148M variant disrupts ubiquitylation and proteasomal degradation of PNPLA3, resulting in accumulation of PNPLA3‐148M and impaired mobilization of TG from LDs. (Hepatology 2017;66:1111‐1124). John Wiley and Sons Inc. 2017-08-26 2017-10 /pmc/articles/PMC5605398/ /pubmed/28520213 http://dx.doi.org/10.1002/hep.29273 Text en © 2017 The Authors. Hepatology published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
BasuRay, Soumik
Smagris, Eriks
Cohen, Jonathan C.
Hobbs, Helen H.
The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation
title The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation
title_full The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation
title_fullStr The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation
title_full_unstemmed The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation
title_short The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation
title_sort pnpla3 variant associated with fatty liver disease (i148m) accumulates on lipid droplets by evading ubiquitylation
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605398/
https://www.ncbi.nlm.nih.gov/pubmed/28520213
http://dx.doi.org/10.1002/hep.29273
work_keys_str_mv AT basuraysoumik thepnpla3variantassociatedwithfattyliverdiseasei148maccumulatesonlipiddropletsbyevadingubiquitylation
AT smagriseriks thepnpla3variantassociatedwithfattyliverdiseasei148maccumulatesonlipiddropletsbyevadingubiquitylation
AT cohenjonathanc thepnpla3variantassociatedwithfattyliverdiseasei148maccumulatesonlipiddropletsbyevadingubiquitylation
AT hobbshelenh thepnpla3variantassociatedwithfattyliverdiseasei148maccumulatesonlipiddropletsbyevadingubiquitylation
AT basuraysoumik pnpla3variantassociatedwithfattyliverdiseasei148maccumulatesonlipiddropletsbyevadingubiquitylation
AT smagriseriks pnpla3variantassociatedwithfattyliverdiseasei148maccumulatesonlipiddropletsbyevadingubiquitylation
AT cohenjonathanc pnpla3variantassociatedwithfattyliverdiseasei148maccumulatesonlipiddropletsbyevadingubiquitylation
AT hobbshelenh pnpla3variantassociatedwithfattyliverdiseasei148maccumulatesonlipiddropletsbyevadingubiquitylation